Analyst Cautions Investors On Overreacting To ‘Early-Stage’ Pfizer/Seagen Discussions
In a news article by the Wall Street Journal, Pfizer Inc (NYSE:PFE) is reportedly in early-stage talks to acquire Seagen Inc (NASDAQ:SGEN) for…
Shionogi’s COVID-19 Pill, Based On Similar Action Like Pfizer’s, Sees Around $2B In Annual Sales
Japanese pharmaceutical company Shionogi & Co Ltd's CEO believes its COVID-19, Xocova, pill can generate $2 billion in annual sales if it secures FDA approval.
The company expects U.S. approval by late 2024.
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 56 companies made new 52-week lows.
Union Pacific, Kosmos Energy, Fisker And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 300 points on Monday. Here are some big stocks recording gains in today’s session.
Nasdaq, S&P 500 Futures Rebound In New Trading Week But Rising Bond Yields Remain A Risk
US stocks are coming off a lackluster week and early indications suggest a reversal in sentiment in the new trading week. While rising bond yields could be a cause of concern, the recent weakness could trigger bargain-hunting-related buying.
Seagen, Occidental Petroleum And 3 Stocks To Watch Heading Into Monday
With US futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Pfizer In Early Talks To Buy Cancer-Focused Seagen: WSJ
Pfizer Inc (NYSE:PFE) is in early discussions to purchase biotechnology company Seagen Inc (NASDAQ:SGEN), The Wall Street Journal reported late on…
Wall Street’s Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
GSK/Pfizer-Backed ViiV Healthcare’s HIV Treatment At Par With Gilead’s: Study Shows
ViiV Healthcare, majority-owned by GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE), and Shionogi Limited, announced 12-month findings from the SOLAR Phase 3b study of the long-acting injectable…
GSK, Pfizer And Shionogi Owned ViiV Healthcare Announced 12-month Findings From The Solar Phase 3B Head-to-head Study Of Long Acting Cabenuva Regime (CAB+RPV LA) Compared Against Gilead’s Biktarvy Regime (BIC/FTC/TAF)
Study findings showed that CAB+RPV LA dosed every two months achieved the primary endpoint of non-inferior virologic efficacy versus daily oral BIC/FTC/TAF, while 90% of participants who switched to CAB+RPV